Skip to main content

Table 1 Baseline demographics and disease characteristics of all randomized patients

From: Intra-articular injections of sodium hyaluronate (Hyalgan®) in osteoarthritis of the knee. a randomized, controlled, double-blind, multicenter trial in the asian population

  Total (n = 200) Hyalgan® (n = 100) Placebo (n = 100) p value
Demographic Characteristic     
Age, mean (SD), yrs 65.0 (8.3) 65.9 (8.1) 64.2 (8.4) NS
Sex, n (%)     
   Male 48 (24.0%) 26 (26.0%) 22 (22.0%) NS
   Female 152 (76.0%) 74 (74.0%) 78 (78.0%) NS
Weight, mean (SD), kg 62.7 (10.2) 63.3 (11.9) 62.1 (8.3) NS
Height, mean (SD), cm 156.5 (7.2) 156.8 (7.7) 156.3 (6.7) NS
BMI, mean (SD), kg/m2 25.6 (3.6) 25.7 (4.3) 25.4 (2.9) NS
Disease Characteristic     
Kellgren-Lawrence grade     
   Grade II (mild), n (%) 119 (59.5%) 59 (59.0%) 60 (60.0%) NS
   Grade III (moderate), n (%) 81 (40.5%) 41 (41.0%) 40 (40.0%) NS
Duration of OA, mean (SD), days 427.0 (1022.5) 499.2 (1190.8) 354.8 (820.5) NS
Clinical Evaluation     
Pain on 50-foot walking test (VAS 0-100 mm) mean (SD) 46.75 (10.59) 47.85 (10.76) 45.65 (10.36) NS
WOMAC A-pain (VAS 0-100 mm) mean (SD) 45.56 (12.12) 45.73 (11.17) 45.39 (13.06) NS
WOMAC C-function(VAS 0-100 mm) mean (SD) 45.99 (12.23) 46.54 (11.31) 45.45 (13.13) NS
  1. SD, standard deviations.
  2. NS, non-significantly different between treatment groups (P > 0.05)